Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6052W HIGH $1.89
Volume
160.82 K
Value Traded
1.09 M
Short % Float
2.97%
-15.53%Week
+4.62%1 Month
+23.64%3 Month
+71.72%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
53.87 M
EPS (TTM)
-0.37
P/E Ratio
-
Ent. Value
52.39 M
Total Shares
39.61 M
Float Shares
35.93 M
Insiders
9.28%
Institutions
36.90%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MYO Catalyst Timeline
Dated clinical, regulatory and corporate events for Myomo Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Myomo Inc.
4Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How MYO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Myomo Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MYO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kovelman HarryOfficer (Chief Medical Officer) | Sell | -15,488 90,245 held | $1.27 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MYO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0 % (-100 %) | 628.00 K | 704.27 K |
MYO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MYO ranks across every disease it competes in
Competitive Position is a premium feature
See how MYO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMYO News
-MYO
Oct 12, 2026▼ -4.9%today
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
Myomo, Inc. has appointed Mary-Katherine McClure as the new Chief Commercial Officer, effective October 12, 2026. She succeeds Micah Mitchell, who is leaving the company after a leadership transition period. McClure brings over 20 years of experience in the industry, which is expected to enhance Myomo's commercial strategies.
Read more →-MYO
Sep 1, 2026Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Myomo, Inc. has announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte Palace Hotel in New York. The company aims to highlight its advancements in wearable medical robotics designed for individuals with neurological disorders and upper-limb paralysis. This event is expected to enhance Myomo's visibility in the investment community.
Read more →-MYO
Aug 5, 2026▲ +23.6%on this news· ran to +42% by day 3
Myomo Reports Second Quarter 2026 Financial and Operating Results
Myomo, Inc. reported its financial results for Q2 2026, highlighting a revenue of $11.7 million, which surpassed expectations. The company attributes this success to an evolved go-to-market strategy aimed at enhancing its offerings for individuals with neurological disorders and upper-limb paralysis. Overall, the results indicate a positive trajectory for Myomo.
Read more →-MYO
Jul 29, 2026▲ +7.5%on this news
Myomo to Report Second Quarter 2026 Financial Results on August 5
Myomo, Inc. has announced the date for its second quarter financial results, which will be reported on August 5, 2026. The company specializes in wearable medical robotics aimed at aiding those with neurological disorders and upper-limb paralysis. A conference call will follow the report to discuss the results and provide business updates.
Read more →-MYO
Jun 16, 2026▲ +6.3%on this news
Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference
Myomo, Inc. announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026. The event will take place on June 23-24, where CEO Paul Gudonis and CFO David Henry will present and meet with investors. A live webcast of the presentation will be available, along with a replay afterward.
Read more →-MYO
May 14, 2026▲ +5.2%on this news
Myomo Announces Participation in Upcoming Investor Conferences
Myomo, Inc. has announced its participation in two upcoming investor conferences. CEO Paul Gudonis and CFO David Henry will engage in a fireside chat at the Alliance Global Partners Annual Healthcare Company Showcase on May 20. Additionally, CFO David Henry will present at Sidoti's Virtual Micro Cap Conference on May 21, which will include one-on-one investor meetings.
Read more →-MYO
May 13, 2026Myomo Appoints Joseph M. Manko to its Board of Directors
Myomo, Inc. has appointed Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026. Manko brings over 25 years of experience in investment banking, private equity, and corporate strategy, including his role as Senior Principal of Horton Capital Management LLC. His addition to the board aims to support Myomo's growth strategy and enhance shareholder value, while the company continues to develop its innovative technology for patients with neurological disorders and upper-limb paralysis.
Read more →-MYO
May 8, 2026▼ -5%on this newsshared move
Myomo Reports First Quarter 2026 Financial and Operating Results
Myomo, Inc. reported its financial results for Q1 2026, achieving revenue of $10.1 million, a 3% increase from the previous year. The company noted a significant shift towards recurring patient revenue sources, which now account for 49% of total revenue. Operating losses decreased, and gross margins improved, indicating positive operational trends. Myomo anticipates continued revenue growth in the upcoming quarter.
Read more →-MYO
May 4, 2026Myomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.
Myomo, Inc. has announced that its MyoPro powered arm brace will be available at Ottobock Care clinics across the U.S. This initiative aims to assist individuals suffering from upper extremity impairments due to conditions such as stroke and brachial plexus injury. The collaboration enhances Ottobock Care's offerings in neuro-robotic solutions for patients.
Read more →-MYO
May 1, 2026Myomo to Report First Quarter 2026 Financial Results on May 7
Myomo, Inc. will announce its financial results for the first quarter of 2026 on May 7. The company specializes in wearable medical robotics for individuals with neurological disorders. A conference call will follow the announcement, allowing management to discuss results and answer questions from participants.
Read more →-MYO
Apr 20, 2026Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement
Myomo, Inc. has launched the Myomo Mobile App to enhance the MyoPro experience for clinicians and patients. This app aims to provide a more intuitive and connected care process, allowing clinicians to customize settings and monitor patient usage effectively. The initiative is expected to improve patient engagement and care management.
Read more →-MYO
Apr 16, 2026Myomo Appoints William J Febbo to its Board of Directors
Myomo, Inc. has appointed William J Febbo to its Board of Directors effective April 14, 2026. Febbo brings over 30 years of experience in healthcare and technology-driven businesses, which is expected to support Myomo's strategic initiatives for 2026 and beyond. He is recognized for his successful track record in guiding organizations through growth and transformation. This addition to Myomo's board is viewed as a crucial step towards strengthening the company's position in the wearable medical robotics market.
Read more →-MYO
Mar 9, 2026Myomo and Elevance Health Agree to Contract for Multi-State Network Participation
Myomo, Inc. has announced a contract with Elevance Health to participate in a multi-state network. This agreement will include Anthem-affiliated plans and is expected to roll out market-by-market through Q2 2026. The deal will increase Myomo's covered lives to over 80 million, enhancing its market presence.
Read more →-MYO
Mar 9, 2026Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Myomo, Inc. reported its financial results for Q4 and the full year of 2025, achieving a revenue of $11.4 million in the fourth quarter and $40.9 million for the year. The company noted that 42% of its fourth quarter revenue came from recurring patient sources. Myomo also announced a revenue guidance for 2026, projecting between $43 million and $46 million, emphasizing its focus on recurring revenue streams.
Read more →-MYO
Mar 2, 2026Myomo to Report Fourth Quarter 2025 Financial Results on March 9
Myomo, Inc. will announce its financial results for Q4 and the full year of 2025 on March 9, 2026. The company, known for its wearable medical robotics, will hold a conference call at 4:30 p.m. ET to discuss the results and provide a business update. This event reflects the company's commitment to transparency.
Read more →-MYO
Nov 10, 2025▲ +6.4%on this news
Myomo Reports Third Quarter 2025 Financial and Operating Results
Myomo, Inc. reported its financial results for Q3 2025, achieving a revenue of $10.1 million. The company noted 229 authorizations and orders, marking its highest count for the year. Myomo also reiterated its full-year revenue guidance, projecting between $40 million and $42 million. A conference call is scheduled for today at 4:30 PM Eastern time.
Read more →-MYO
Nov 3, 2025Myomo to Report Third Quarter 2025 Financial Results on November 10
Myomo, Inc. will announce its financial results for Q3 2025 on November 10, 2025. The company specializes in wearable medical robotics aimed at aiding those with neurological disorders and upper-limb paralysis. A conference call will follow the announcement to discuss results and provide updates.
Read more →-MYO
Sep 2, 2025Myomo at H.C. Wainwright 27th Global Conference
Myomo, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Paul Gudonis and CFO David Henry will represent the company, which focuses on wearable robotics for individuals with neurological disorders. A presentation will be available on demand, and management will hold virtual meetings with investors.
Read more →About Myomo Inc.
Headquarters137 PORTLAND STREET, BOSTON, MA, 02114
BIOPHARMAWATCH ELITE PLUS
Trade the next MYO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime